Placebo News and Research

RSS

What is the optimal duration of antibiotic therapy?

Taking antibiotics for three days is just as effective for community acquired pneumonia as continuing treatment for the recommended 7-10 days, finds a study in this week's British Medical Journal.

8 Jun 2006

FDA approval of Gardasil to prevent cervical cancer

The Food and Drug Administration (FDA) has announced the approval of Gardasil, the first vaccine developed to prevent cervical cancer, precancerous genital lesions and genital warts due to human papillomavirus (HPV) types 6, 11, 16 and 18.

8 Jun 2006

Health education helps African American smokers quit

The first clinical trial to focus on light smokers shows that African Americans are motivated to quit more by completing health education than by using nicotine gum.

7 Jun 2006

Calcium and vitamin D supplements do not reduce breast cancer

A large multicenter randomized clinical trial reported that supplementation with calcium and vitamin D did not reduce breast cancer risk in the overall population.

7 Jun 2006

New research on brain, hormones and behavior

New clinical and basic science research findings focusing on the interaction between hormones and the brain and its influence on behavior will be presented for the first time at the 6th International Congress of Neuroendocrinology.

6 Jun 2006

Atorvastatin may increase new blood vessel formation

Systemic sclerosis (SSc), also known as scleroderma, is an uncommon and confounding disease characterized by excessive fibrous tissue formation and vascular abnormalities.

6 Jun 2006

New drug combo to cut cardiovascular disease

A major international study to test whether a new combination treatment that increases good "HDL" cholesterol prevents heart attacks and strokes will start to recruit patients later this year.

6 Jun 2006

Advanced prostate cancer can be treated successfully with intermittent chemotherapy

Advanced prostate cancer can be treated successfully with intermittent chemotherapy, according to a study conducted by Oregon Health & Science University Cancer Institute scientists.

6 Jun 2006

New vaccine reduces the risk of shingles

A new vaccine which reduces the risk of shingles (herpes zoster) for use in people 60 years of age and older has won approval from the U.S. Food and Drug Administration.

29 May 2006

Higher dose of flu vaccine improves immune response in the elderly

There may be a simple way to provide elderly Americans with extra protection against the annual flu virus: give them a higher dose of seasonal flu vaccine.

23 May 2006

High-dose influenza vaccines boost immunity in elderly

High-dose influenza vaccines may increase elderly patients' immune response without significant adverse effects, offering this vulnerable population additional protection against the flu, according to an article in the Archives of Internal Medicine.

23 May 2006

Nutritional supplement policosanol does not lower cholesterol levels

A new study suggests that use of the nutritional supplement policosanol does not lower cholesterol levels any more than placebo, apparently contradicting the results of previous studies.

23 May 2006

New rheumatoid arthritis drugs may put patients at risk of infections and cancer

Anti-TNF (tumor necrosis factor) therapies are a tried and tested type of medication used for treating rheumatoid arthritis and the drugs provide benefit to many of thousands of patients worldwide.

21 May 2006

FDA approves Azilect for the treatment of Parkinson's

The Food and Drug Administration today approved Azilect (rasagiline), a new molecular entity, for the treatment of Parkinson's disease.

17 May 2006

Vaccine against cervical cancer on track for FDA approval

According to the Food and Drug Administration in the U.S. an experimental vaccine which prevents cervical cancer appears to be effective and has no major safety concerns.

17 May 2006

Study shows strong association between treatment with TNF-blocking antibodies and development of serious infections

A new meta-analysis of many previous studies of TNF- (tumor necrosis factor) blocking antibodies for treatment of rheumatoid arthritis has confirmed a previously discovered increased risk for serious infection and has found that cancer also is a potential risk associated with the drugs.

17 May 2006